BriaCell and BriaPro Close Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell and BriaPro announced the completion of an asset purchase transaction for the exclusive soluble CD80 license. BriaPro acquired the license and associated assets from BriaCell, with BriaCell retaining a 2% royalty and receiving $3 million in funding for research and development. In exchange, BriaCell received 23.97 million common shares, increasing its interest in BriaPro to approximately 78%. Jamieson Bondarenko was appointed BriaPro Board Chair following the transaction.